Daratumumab Use Prior to Kidney Transplant and T Cell-Mediated Rejection: A Case Report

Am J Kidney Dis. 2023 May;81(5):616-620. doi: 10.1053/j.ajkd.2022.11.010. Epub 2023 Jan 6.


There is growing interest in daratumumab in the solid organ transplant realm owing to the potential immunomodulatory effects on CD38-expressing cells, primarily plasma cells, as they have a key role in antibody production. In particular there is interest in use of daratumumab for desensitization and potential treatment for antibody-mediated rejection. However, ongoing investigation with daratumumab has shown potential immunologic concerns in vitro, with a significant increase in populations of CD4-positive cytotoxic T cells and CD8-positive helper T cells in both peripheral blood and bone marrow that could lead to acute T cell-mediated rejection in the solid organ transplant patient. To date, there are no published reports of an association with daratumumab use and T cell-mediated rejection in vivo. In this case report we present what is to our knowledge the first documented case of an early severe T cell-mediated rejection in a low-immunologic-risk living-donor kidney transplant recipient who received daratumumab for multiple myeloma maintenance prior to transplant.

Keywords: Acute cellular rejection; Adverse event; Anti-CD38 monoclonal antibody; Case report; Daratumumab; Kidney transplantation; Multiple myeloma; T cell–mediated rejection.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1
  • Antibodies, Monoclonal / therapeutic use
  • Humans
  • Kidney Transplantation*
  • Multiple Myeloma* / therapy
  • T-Lymphocytes


  • daratumumab
  • ADP-ribosyl Cyclase 1
  • Antibodies, Monoclonal